According to Morgan Stanley, Amylin Pharmaceuticals AMLN risks remain.
Morgan Stanley said that it believes the latest update on the ongoing Amylin/Lilly legal battle accentuates the risks to Amylin. “While this decision is not on the breach of contract, we see most outcomes of that decision, discussed below, as potentially negative for Amylin.”
Amylin Pharmaceuticals closed yesterday at $12.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in